CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Radiopharm Theranostics Plans Phase 3 RAD101 Brain Metastases Imaging Trial in Q1 2027

By Public Technologies
  • Radiopharm Theranostics expects to start a pivotal Phase 3 imaging trial of RAD101 for recurrent brain metastases in the first quarter of 2027.
  • The planned trial follows a successful FDA end-of-Phase 2 meeting in October 2026; previously reported results met the primary endpoint.
  • Interim Phase 2b imaging results supporting Phase 3 development will be presented at the Society for Neuro-Oncology meeting on November 12-15, 2026.
  • Siemens Healthineers will manufacture and distribute RAD101 doses for the US portion of the Phase 3 registrational trial.
  • RAD301 Phase 1 results reported in September 2026 showed favorable safety and tumor uptake in pancreatic cancer, supporting advancement toward Phase 2.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radiopharm Theranostics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611020800PRIMZONEFULLFEED1001301154) on November 02, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk